Abstract
Objectives: The Ebola virus is an extraordinarily deadly illness that affects both humans and wild animals. Key elements in viral proliferation include viral adhesion to cell membranes and viral penetration into the host organism. The viral protein present in the Ebola virus is the matrix protein Viral Protein-40 (VP-40) which is required for the development and integration of the nucleocapsid. Limiting VP40 activity prevents the viral infection from spreading. Methods: Ten phytochemicals from Acacia caven were examined for their physicochemical properties, drug-likeness, and their potential to impede VP40 to assess their potential as anti-Ebola virus therapeutics. Results: Considering the pharmacological uses, ten bioactive chemicals were chosen for this investigation. Predicated on their docking score and binding interactions, Pimara-8(14), 15-diene, Heptacosane, and Geranylacetone were recognized as VP-40 inhibitors. Conclusion: Developing medicines that can inhibit VP40 could be a potential anti-Ebola virus treatment solution as VP40 is a fundamental protein for the assemblage of virion. Using the ligands Geranylacetone, Heptacosane, and Pimara-8(14), 15-diene, anti-Ebola virus therapeutics can be developed that specifically target the VP40 suppression which aids in the management of Ebola Virus disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
